A small cell lung cancer (SCLC) misdiagnosis is possible. This can occur because of challenges during the diagnostic tests and because SCLC may share symptoms and causes similar to other conditions.

Durvalumab cost-effectiveness in limited-stage small cell lung cancer failed to meet US value thresholds despite longer ...

A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living ...

BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01 phase 2 trial showed ifinatamab deruxtecan (I-DXd) ...

Researchers have identified a previously unknown inflammatory mechanism that may drive the aggressiveness and relapse of ...

The phase 3 IMforte trial(NCT05091567) demonstrated benefit for expanding on maintenance immunotherapy in extensive-stage ...

A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor ...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ...

The anti-cancer drug durvalumab used in immunotherapy delivers a 66-month survival breakthrough for lung cancer patients, ...

LEMS is an autoimmune disorder linked to SCLC, causing muscle weakness and autonomic dysfunction due to presynaptic calcium channel antibodies. Differentiation from myasthenia gravis involves ...